Mycobacterium gordonae Infection Follow-up

Updated: Sep 08, 2017
  • Author: Klaus-Dieter Lessnau, MD, FCCP; Chief Editor: Mark R Wallace, MD, FACP, FIDSA  more...
  • Print
Follow-up

Further Outpatient Care

Treat in an outpatient setting. Evaluate the patient monthly for adverse effects.

Next:

Further Inpatient Care

M gordonae infections should be treated until symptoms resolve. Prolonging treatment may prevent relapse, but the optimal treatment duration is unknown. Three, 6, and 12 months of therapy have been used. The improvement of objective abnormalities (eg, chest radiograph findings) may also be useful in determining the optimal duration of treatment. If the treatment time is too short, relapse may occur. If the treatment time is too long, the adverse effects of medication may become a concern.

Isolation is not indicated (once active tuberculosis infection is excluded); however, the presence of acid-fast organisms on a stain should prompt immediate isolation unless the patient is clearly not acutely contagious.

Previous
Next:

Inpatient & Outpatient Medications

At least 2 daily drugs are indicated for documented M gordonae disease. Intermittent therapy has not been evaluated.

Previous
Next:

Transfer

Transfer to other facilities is unnecessary. Consultation with an expert from the National Jewish Medical and Research Center in Denver, Colo; Centers for Disease Control and Prevention in Atlanta, Ga; local infectious disease experts; or the department of health may be useful.

Previous
Next:

Complications

Dissemination is a concern. Death is an unlikely outcome, except in patients who are severely immunocompromised, such as CD4+ cell counts in the single digits.

Monotherapy may induce resistance.

Previous
Next:

Prognosis

With treatment, the reported prognosis of M gordonae infection is excellent.

Previous
Next:

Patient Education

Inform patients that they are not infectious and are not dangerous to other people.

Previous